Survivin as Predictive Biomarker for RA

NCT03444623 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 6000

Last updated 2022-05-04

No results posted yet for this study

Summary

Purpose: to examine the possibility of using the onco-protein survivin as a predictive biomarker for identifying individuals at risk of developing rheumatoid arthritis within a cohort of patients seeking treatment for joint pain/stiffness. Secondly, to study survivin as a prognostic marker for joint destruction, refractory and highly active disease in patients with established RA.

Conditions

Sponsors & Collaborators

  • Vastra Gotaland Region

    lead OTHER_GOV

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2023-06-30
Completion
2023-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03444623 on ClinicalTrials.gov